Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

NCT01317186 is registered in ClinicalTrials.gov with Ankara Education and Research Hospital as lead sponsor.

NCT NCT01317186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01317186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease
Lead sponsor
Ankara Education and Research Hospital
Phase
Observational
Overall status
Unknown status
Start date
March 31, 2011
Completion date
Not reported
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, metabolic diseases